Tag: Daniel O’Day
Gilead gets Trodelvy FDA approval for pre-treated HR+/HER2- metastatic breast cancer
Gilead Sciences has secured the approval of the US Food and Drug Administration (FDA) for Trodelvy (sacituzumab govitecan-hziy) for pre-treated HR+/HER2- metastatic breast cancer. The ... Read More
Gilead Sciences gets Sunlenca FDA approval for multi-drug resistant HIV
Sunlenca FDA approval : Gilead Sciences has secured the approval of the US Food and Drug Administration (FDA) for Sunlenca (lenacapavir), in combination with other ... Read More
Gilead Sciences gets Veklury FDA approval for non-hospitalized Covid-19 patients
Gilead Sciences has secured expedited approval from the US Food and Drug Administration (FDA) for its nucleotide analog Veklury (remdesivir) for the treatment of non-hospitalized ... Read More
Gilead Sciences to acquire HDV drug developer MYR in €1.4bn deal
Gilead Sciences acquisition of MYR : US biopharma giant Gilead Sciences has agreed to acquire MYR, a German biotech company engaged in developing therapies for ... Read More
Gilead Sciences wraps up $21bn acquisition of Immunomedics
Gilead Sciences has wrapped up its previously announced $21 billion acquisition of New Jersey-based biopharma company Immunomedics. With the completion of the deal, Immunomedics has ... Read More
Gilead Sciences bags Remdesivir FDA approval for Covid-19 treatment
Remdesivir FDA approval : Gilead Sciences, a California-based biopharma company, has bagged approval from the US Food and Drug Administration (FDA) for its antiviral drug ... Read More
Gilead, Galapagos bag Jyseleca EC approval for rheumatoid arthritis
Jyseleca EC approval : Gilead Sciences and Galapagos have secured marketing authorization for Jyseleca (filgotinib 200 mg and 100 mg tablets) from the European Commission ... Read More
Gilead acquisition of Immunomedics : Pharma giant to gain access to breast cancer drug Trodelvy
Gilead acquisition of Immunomedics : US pharma giant Gilead Sciences has signed a $21 billion worth deal to acquire New Jersey-based biopharma company Immunomedics to ... Read More
Gilead to acquire stake in cancer immunotherapy company Pionyr Immunotherapeutics
Gilead Sciences has agreed to acquire a stake of 49.9% in California-based cancer immunotherapy company Pionyr Immunotherapeutics, for $275 million. The pharma major has also ... Read More
FDA grants EUA for Gilead’s investigational COVID-19 drug remdesivir
Remdesivir EUA status : The US has officially pushed the use of remdesivir for treating the novel coronavirus with the Food and Drug Administration (FDA) ... Read More